Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIAM vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Treatment of mild to moderate acute malaria caused by Plasmodium falciparum (including chloroquine-resistant strains) or Plasmodium vivax,Prophylaxis of malaria in travelers to areas with chloroquine-resistant P. falciparum,Off-label: treatment of chloroquine-sensitive malaria when other agents are not available
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Terminal elimination half-life: approximately 3 weeks (range 13–33 days); prolonged due to extensive tissue distribution and slow release from erythrocytes.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Primarily metabolized by cytochrome P450 (CYP) 3A4 to inactive metabolites. It also undergoes enterohepatic recirculation.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Hepatic metabolism (primarily CYP3A4) followed by biliary/fecal elimination; ~40% unchanged in feces, ~9% as metabolites in urine, minimal renal excretion of parent drug (<5%).
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
Vd: 15–30 L/kg; extensive distribution into tissues, including erythrocytes (high concentration), liver, lungs, and spleen.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: ~85% (well absorbed); not available parenterally in the US.
Oral: 80-90%.
No specific dosing adjustment required for renal impairment, but caution in GFR <30 m L/min due to limited data; monitor for adverse effects.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
Contraindicated in patients with significant hepatic impairment (Child-Pugh class B or C). For mild impairment (Child-Pugh class A), no adjustment needed but use with caution.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
Prophylaxis and treatment: 15-25 mg base/kg orally; maximum 1250 mg. For children weighing ≤45 kg: 5 mg base/kg weekly for prophylaxis; for treatment, same mg/kg as adults. Dosing based on mefloquine base. Not recommended for children <5 kg or <3 months.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
No specific dose adjustment, but monitor for neuropsychiatric and cardiac effects (QT prolongation, bradycardia). Use caution due to age-related decline in hepatic and renal function, and potential drug interactions.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
WARNING: Mefloquine can cause serious psychiatric and neurological adverse reactions, including suicide, hallucinations, anxiety, depression, paranoia, confusion, dizziness, and seizures. Use caution in patients with recent history of depression, generalized anxiety disorder, psychosis, or schizophrenia. Discontinue immediately if psychiatric or neurological symptoms occur. Not recommended for prophylaxis in patients with active or recent depression, generalized anxiety disorder, psychosis, or schizophrenia.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Psychiatric effects: suicidal ideation, hallucinations, anxiety, depression; Neurologic effects: dizziness, vertigo, seizures; QT prolongation (caution with drugs that prolong QT); use in pregnancy only if benefit outweighs risk; avoid in patients with cardiac conduction disorders; may cause visual disturbances; use caution with activities requiring alertness.
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
History of hypersensitivity to mefloquine or related compounds (e.g., quinine); active or recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorders; history of convulsions or epilepsy; concurrent use with halofantrine or other drugs that prolong QT interval.
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Grapefruit juice may increase mefloquine concentrations and risk of side effects; avoid concurrent use. Take with food or milk to reduce gastrointestinal upset. No other significant food interactions.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
Pregnancy Category C. In animal studies, mefloquine (LARIAM) has been shown to be teratogenic in mice (cleft palate, anophthalmia) and rats (hydrocephalus, anophthalmia) at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Because malaria infection in pregnancy carries significant maternal and fetal risk, treatment of confirmed malaria with mefloquine is not contraindicated. Prophylaxis should be avoided in pregnancy unless travel to a high-risk area is unavoidable. First trimester: known fetal risks; second and third trimesters: limited data suggest no increased malformations, but caution advised.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Mefloquine is excreted in human breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Studies indicate that the amount ingested by a nursing infant is about 3-4% of the maternal weight-adjusted dose, which is below the therapeutic pediatric dose. The American Academy of Pediatrics considers mefloquine compatible with breastfeeding. Monitor infant for potential adverse effects (e.g., gastrointestinal disturbance, sleep disturbance).
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No specific dosing adjustments are routinely recommended for mefloquine in pregnancy based on pharmacokinetic changes. Pregnancy may alter drug disposition, but studies show mefloquine clearance is not significantly changed. Standard adult dosing for prophylaxis (250 mg once weekly) and treatment (1250 mg in divided doses) is generally used. However, due to increased volume of distribution and altered protein binding in pregnancy, some experts consider an increased dose or more frequent monitoring for efficacy, especially in second and third trimesters. Current guidelines (CDC, WHO) do not mandate dose adjustment, but caution is advised in malaria treatment to ensure adequate exposure.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Lariam (mefloquine) is used for malaria prophylaxis and treatment. Neuropsychiatric effects (anxiety, depression, hallucinations) can occur even weeks after discontinuation. Caution in patients with history of seizures or psychiatric disorders. Use with caution in patients with cardiac conduction abnormalities due to potential QT prolongation. Administer with food to reduce gastrointestinal side effects. Not recommended for patients with severe hepatic impairment.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take exactly as prescribed, usually once weekly for prophylaxis starting 2 weeks before travel and continuing for 4 weeks after leaving area.,Report any symptoms of anxiety, depression, confusion, or unusual dreams immediately.,May cause dizziness or balance problems; avoid driving or operating machinery until reaction is known.,Use effective contraception during treatment and for 3 months after last dose as it may cause fetal harm.,Avoid grapefruit juice as it may increase side effects.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIAM vs ARALEN, answered by our medical review team.
LARIAM is a Antimalarial that works by Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIAM and ARALEN depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIAM is: For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIAM and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIAM is classified as Category C. Pregnancy Category C. In animal studies, mefloquine (LARIAM) has been shown to be teratogenic in mice (cleft palate, anophthalmia) and rats (hydrocephalus, anophthalmia) at doses s. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.